Baseline observations from the POSSIBLE EU® study: characteristics of postmenopausal women receiving bone loss medications
Open Access
- 27 February 2010
- journal article
- research article
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 5 (1-2) , 61-72
Abstract
Summary Prospective Observational Scientific Study Investigating Bone Loss Experience in Europe (POSSIBLE EU®) is an ongoing longitudinal cohort study that utilises physician- and patient-reported measures to describe the characteristics and management of postmenopausal women on bone loss therapies. We report the study design and baseline characteristics of 3,402 women recruited from general practice across five European countries. Purpose The POSSIBLE EU® is a study describing the characteristics and management of postmenopausal women receiving bone loss medications. Methods Between 2005 and 2008, general practitioners enrolled postmenopausal women initiating, switching or continuing treatment with bone loss treatment in France, Germany, Italy, Spain and the UK. Patients and physicians completed questionnaires at study entry and at 3-month intervals, for 1 year. Results Of 3,402 women enrolled (mean age 68.2 years [SD] 9.83), 96% were diagnosed with low bone mass; 55% of these using dual energy X-ray absorptiometry. Most women (92%) had comorbidities. Mean minimum T score (hip or spine) at diagnosis was −2.7 (SD 0.89; median −2.7 [interquartile range, −3.2, −2.2]) indicating low bone mineral density. Almost 40% of the women had prior fractures in adulthood, mostly non-vertebral, non-hip in nature, 30% of whom had at least two fractures and more than half experienced moderate/severe pain or fatigue. Bisphosphonates were the most common type of bone loss treatment prescribed in the 12 months preceding the study. Conclusions POSSIBLE EU® characterises postmenopausal women with low bone mass, exhibiting a high rate of prevalent fracture, substantial bone fragility and overall comorbidity burden. Clinical strategies for managing osteoporosis in this population varied across the five participating European countries, reflecting their different guidelines, regulations and standards of care.Keywords
This publication has 12 references indexed in Scilit:
- Design of the POSSIBLE US™ Study: postmenopausal women’s compliance and persistence with osteoporosis medicationsOsteoporosis International, 2008
- Osteoporosis treatment and fracture incidence: the ICARO longitudinal studyOsteoporosis International, 2008
- European guidance for the diagnosis and management of osteoporosis in postmenopausal womenOsteoporosis International, 2008
- Assessment of non-vertebral fracture risk in postmenopausal womenAnnals of the Rheumatic Diseases, 2007
- Non-compliance: the Achilles' heel of anti-fracture efficacyOsteoporosis International, 2007
- Prediction of absolute risk of non-spinal fractures using clinical risk factors and heel quantitative ultrasoundOsteoporosis International, 2007
- Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO)QJM: An International Journal of Medicine, 2006
- Identification of Osteopenic Women at High Risk of Fracture: The OFELY StudyJournal of Bone and Mineral Research, 2005
- EuroQol: the current state of playHealth Policy, 1996
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990